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haustive information concerning all the patients having
undergone MOS in the year 1998 in France. These pa-
tients were stratified based on the presence or absence of
a listed secondary diagnosis of DVT or PE. Length of stay
in hospital and cost of inpatient care were then compared
between patients with and without secondary diagnosis
of VTE. RESULTS: 105,952 hospital stays, 37,034 and
58,135 were respectively recorded for hip replacement,
knee replacement and hip fracture. Rates of VTE were re-
corded to be 1.4% and 2.6% for hip replacement and
knee replacement respectively. For each primary Diagno-
sis Related Group, the length of stay was shown to be sig-
nificantly higher in case of occurrence of VTE complica-
tions (19.1 days versus 15.1 for hip replacement, 18 days
versus 15.2 for knee replacement, 21.4 days versus 13.8
for hip fracture). Consequently, total costs of inpatient
care were substantially higher for patients with VTE
complications. CONCLUSION: The rates of VTE ob-
served from the National inpatient database provide in-
formation on the frequency of VTE complications after
MOS in real setting. In patients undergoing major ortho-
pedic surgery, the occurrence of VTE is associated with a
longer hospital stay and higher cost of inpatient care.
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OBJECTIVE: To perform an analysis of the cost of ad-
verse events (AEs) associated with treatment by atorva-
statin, fluvastatin, lovastatin, pravastatin, and simvasta-
tin following NCEP low density lipoprotein-cholesterol
(LDL-C) guidelines. METHODS: Data come from a 54-
week randomized, open-label, double-blind controlled
trial conducted in 158 US centers between May 1997 and
January 1999. Patients (n  3916) with or without coro-
nary heart disease and/or peripheral vascular disease
were randomized to receive atorvastatin (n  1958), flu-
vastatin (n  497), lovastatin (n  498), pravastatin (n 
481), and simvastatin (n  482). Inclusion criteria in-
cluded elevated LDL-C for patients 18–80 years of age.
Exclusion criteria included known hypersensitivity to
HMG-CoA reductase inhibitors, use of selected medica-
tions, and other patient characteristics. Data were col-
lected on AEs. RESULTS: A total of 9707 AEs were re-
ported during the trial. Of these AEs, 1327 (14%) were
related to the use of study medications. Related AEs in-
volved the digestive system (387, 29%), musculoskeletal
system (356, 27%), central nervous system (269, 20%),
skin (124, 9%), abnormal laboratory values (68, 5%),
respiratory system (40, 3%), urogenital system (25, 2%),
cardiovascular system (24, 2%), and miscellaneous (35,
3%). The 1327 medication related AEs were associated
with the use of 1384 medical services. Many AEs were
treated at scheduled study visits (239, 18%) and did not
involve additional costs. Additional medical services typi-
cally consisted of physician office visits. There was one
hospitalization (gastroenteritis). Costs of AEs were mea-
sured at Medicare payment rates—a third party perspec-
tive. The average cost of treating AEs were similar among
study arms: atorvastatin $27.78, fluvastatin $31.78, lov-
astatin $26.58, pravastatin $25.17, and simvastatin
$32.58 (no differences were significant at p  0.1).
CONCLUSIONS: Results suggest that the cost associated
with adverse events related to study medications did not
vary significantly among HMG-CoA reductase inhibitors
used to treat patients with elevated cholesterol levels.
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OBJECTIVES: To assess patients’ quality of life (HQL)
post-myocardial infarction and to identify related vari-
ables. METHODS: Patients admitted to the University of
Michigan Medical Center with diagnosis of MI were
identified consecutively and prospectively from October
1999 to May 2000. Clinical data were obtained retro-
spectively from medical records. Six months after dis-
charge, patients were administered the Short Form-12
(SF-12), via telephone, to determine physical (PCS-12)
and mental (MCS-12) functional status. RESULTS:
Complete information was obtained from 148 patients.
The mean age of patients was 64.7 years (13.2) and
79.1% were male. The mean PCS-12 scores were 35.4
(9.12), and the mean MCS-12 scores were 51.6
(10.01). The median PCS-12 scores were significantly
lower in patients with an ejection fraction (EF) 40%
(31.9 versus 38.4 for EF340%, p  0.02), and prior MI
(31.2 versus 38.5 without a history of MI, p  0.01),
congestive heart failure (CHF) (32.6 versus 37.4 without
a history of CHF, p  0.03), renal insufficiency (27.9
versus 37.7, p  0.003), or peripheral vascular disease
(29.4 versus 38.2 without a history of PVD, p  0.004).
The median MCS-12 scores were significantly lower for
patients under 65 years of age (49.6 versus 57.4 for pa-
tients 365 years of age, p  0.001) and with a history of
coronary artery bypass graft (CABG) (60.1 versus 54.7
without history of CABG, p  0.01). There were no dif-
ferences detected between gender, type of MI, diabetes,
hypertension, angina, or smoking. CONCLUSIONS: HQL
scores were lower for patients post-MI with various co-
morbidities. Physical scores were significantly lower for
patients with low EFs, prior MI, or CHF. Mental scores
were significantly lower for patients 65 and those not
having already undergone CABG surgery. Post-MI, par-
ticular attention should be paid to these patients. Further
